Elevated plasma ferritin in elderly individuals with high neocortical amyloid-β load

Molecular Psychiatry

Volumn 23, Issue 8, 2018, Pages 1807-1812

  Goozee, K ^{a,b,c,d,e,f,g}   Chatterjee, P ^a,d,f   James, I ^h   Shen, K ⁱ   Sohrabi, H R ^a,d,e,g   Asih, P R ^f,j   Dave, P ^a,b   ManYan, C ^b   Taddei, K ^d,e   Ayton, S J ^k   Garg, M L ^l   Kwok, J B ^j,m   Bush, A I ^g,k   Chung, R ^a   Magnussen, J S ^a   Martins, R N ^a,c,d,e,f,g  

^a MACQUARIE UNIVERSITY   (Australia)

^b Anglicare   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d EDITH COWAN UNIVERSITY   (Australia)

^e McCusker Alzheimer's Research foundation   (Australia)

^f KaRa Institute of Neurological Disease   (Australia)

^g University of Melbourne   (Australia)

^h MURDOCH UNIVERSITY   (Australia)

ⁱ CSIRO   (Australia)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

^k UNIVERSITY OF MELBOURNE   (Australia)

^l UNIVERSITY OF NEWCASTLE   (Australia)

^m NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; C REACTIVE PROTEIN; FERRITIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE MARKER; FEMALE; FERRITIN BLOOD LEVEL; GENDER; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOCORTEX; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; BLOOD; COHORT ANALYSIS; DIAGNOSTIC IMAGING; GENETICS; METABOLISM; ORGAN SIZE; PRODROMAL SYMPTOM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOMARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FERRITINS; HUMANS; MALE; NEOCORTEX; ORGAN SIZE; POSITRON-EMISSION TOMOGRAPHY; PRODROMAL SYMPTOMS; SENSITIVITY AND SPECIFICITY;

EID: 85053844913     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2017.146     Document Type: Article

References (39)

1. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004; 5: 863–873.
2. Benarroch EE. Brain iron homeostasis and neurodegenerative disease. Neurology 2009; 72: 1436–1440.
3. van Rooden S, Doan NT, Versluis MJ, Goos JD, Webb AG, Oleksik AM et al. 7TT(2)*-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease. Neurobiol Aging 2015; 36: 20–26.
4. Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW Jr, Cohen ML et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 2010; 19: 363–372.
5. Belaidi AA, Bush AI. Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics. J Neurochem 2016; 139(Suppl 1): 179–197.
6. Ayton S, Faux NG, Bush AI. Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. Nat Commun 2015; 6: 6760.
7. Ayton S, Faux NG, Bush AI. Association of cerebrospinal fluid ferritin level with preclinical cognitive decline in APOE-epsilon4 carriers. JAMA Neurol 2017; 74: 122–125.
8. Giambattistelli F, Bucossi S, Salustri C, Panetta V, Mariani S, Siotto M et al. Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer's disease. Neurobiol Aging 2012; 33: 1633–1641.
9. Faux NG, Rembach A, Wiley J, Ellis KA, Ames D, Fowler CJ et al. An anemia of Alzheimer's disease. Mol Psychiatry 2014; 19: 1227–1234.
10. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013; 12: 357–367.
11. O'Bryant SE, Lista S, Rissman RA, Edwards M, Zhang F, Hall J et al. Comparing biological markers of Alzheimer's disease across blood fraction and platforms: comparing apples to oranges. Alzheimers Dement (Amst) 2016; 3: 27–34.
12. Ji Y, Faddy H, Hyland C, Flower R. A plasma ferritin is not always a serum ferritin. Pathology 2015; 47(Suppl 1): S89–S90.
13. Hsieh SY, Chen RK, Pan YH, Lee HL. Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling. Proteomics 2006; 6: 3189–3198.
14. Rossetti HC, Lacritz LH, Cullum CM, Weiner MF. Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology 2011; 77: 1272–1275.
15. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263–269.
16. Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J et al. A blood-based predictor for neocortical Abeta burden in Alzheimer's disease: results from the AIBL study. Mol Psychiatry 2014; 19: 519–526.
17. 11C PiB PET. PLoS ONE 2014; 9: e84777.
18. Bourgeat P, Villemagne VL, Dore V, Brown B, Macaulay SL, Martins R et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging 2015; 36(Suppl 1): S159–S166.
19. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009; 21: 672–687.
20. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
21. Connor JR, Menzies SL St, Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 1992; 31: 75–83.
22. Li X, Liu Y, Zheng Q, Yao G, Cheng P, Bu G et al. Ferritin light chain interacts with PEN-2 and affects gamma-secretase activity. Neurosci Lett 2013; 548: 90–94.
23. Kwiatek-Majkusiak J, Dickson DW, Tacik P, Aoki N, Tomasiuk R, Koziorowski D et al. Relationships between typical histopathological hallmarks and the ferritin in the hippocampus from patients with Alzheimer's disease. Acta Neurobiol Exp 2015; 75: 391–398.
24. Banerjee P, Sahoo A, Anand S, Bir A, Chakrabarti S. The oral iron chelator, deferasirox, reverses the age-dependent alterations in iron and amyloid-beta homeostasis in rat brain: implications in the therapy of Alzheimer's disease. J Alzheimers Dis 2015; 49: 681–693.
25. Bester J, Buys AV, Lipinski B, Kell DB, Pretorius E. High ferritin levels have major effects on the morphology of erythrocytes in Alzheimer's disease. Front Aging Neurosci 2013; 5: 88.
26. Hare DJ, Doecke JD, Faux NG, Rembach A, Volitakis I, Fowler CJ et al. Decreased plasma iron in Alzheimer's disease is due to transferrin desaturation. ACS Chem Neurosci 2015; 6: 398–402.
27. Bartzokis G, Tishler TA, Shin IS, Lu PH, Cummings JL. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann N Y Acad Sci 2004; 1012: 224–236.
28. Quintana C, Bellefqih S, Laval JY, Guerquin-Kern JL, Wu TD, Avila J et al. Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J Struct Biol 2006; 153: 42–54.
29. Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics 2014; 6: 748–773.
30. Hazard JT, Drysdale JW. Ferritinaemia in cancer. Nature 1977; 265: 755–756.
31. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: past, present and future. Biochim Biophys Acta 2010; 1800: 760–769.
32. Theil EC. Ferritin: the protein nanocage and iron biomineral in health and in disease. Inorg Chem 2013; 52: 12223–12233.
33. Raven EP, Lu PH, Tishler TA, Heydari P, Bartzokis G. Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging. J Alzheimers Dis 2013; 37: 127–136.
34. O'Bryant SE, Waring SC, Hobson V, Hall JR, Moore CB, Bottiglieri T et al. Decreased C-reactive protein levels in Alzheimer disease. J Geriatr Psychiatry Neurol 2010; 23: 49–53.
35. Su XW, Clardy SL, Stephens HE, Simmons Z, Connor JR. Serum ferritin is elevated in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 2015; 16: 102–107.
36. 11C] PiB-PET brain amyloid burden. PLoS ONE 2012; 7: e44260.
37. Thambisetty M, Tripaldi R, Riddoch-Contreras J, Hye A, An Y, Campbell J et al. Proteome-based plasma markers of brain amyloid-beta deposition in non-demented older individuals. J Alzheimers Dis 2010; 22: 1099–1109.
38. Ashton NJ, Kiddle SJ, Graf J, Ward M, Baird AL, Hye A et al. Blood protein predictors of brain amyloid for enrichment in clinical trials? Alzheimer’s Dement 2015; 1: 48–60.
39. O'Bryant SE, Xiao G, Barber R, Reisch J, Hall J, Cullum CM et al. A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord 2011; 32: 55–62.